Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Inc. is trading at $15.55, down 1.77% on the session. The 50 day average sits at $15.74 and the 200 day at $16.28, which puts the stock in a downtrend. RSI is at 49.3, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $15.18 with resistance near $18.33, so that band frames the current range. Average daily movement is roughly $1.03, or about 6.6% of the share price, which is what any stop placement has to allow for. The overall health score of 37 out of 100 combines a trend score of 27, momentum of 38 and a risk score of 52.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.